Table 2.
Seroconversion Rates in Patients With CLL for First, Second, and Third Dose of Vaccines
| Author | Response (n Evaluable) | |||
|---|---|---|---|---|
| N | First Dose Response | Second Dose Response | Third Dose Response | |
| Bagacean et al (2022)32 | 530 | 27% (158) | 52% (506) | 35% (95)a |
| Dong et al (2021)30 | 23 | 21.7% (23) | 65.2% (23) | NA |
| Shen et al (2021)27 | 160 | 20.8% (125) | 55.0% (160) | NA |
| Herishanu et al (2022)42 | 172 | NA | NA | 23.8% (172)a |
| Greenberger et al (2021)43 | 25 | NA | NA | 80% (25)b |
| Del Poeta et al (2021)44 | 46 | NA | NA | 54.3% (46)c |
| Haydu et al (2022)41 | 36 | NA | NA | 55% (11)a |
| Giuliano et al (2022)25 | 23 | 21.7% (23) | 65.2% (23) | NA |
| Šušol et al (2022)24 | 53 | NA | NA | 0% (15)a |
| Teh et al (2021)21,d | 1446 | 18% (111) | 51% (1446) | NA |
aSeronegative after initial vaccine series.
b72% seronegative after initial vaccination.
cInitial vaccination response not reported.
dMeta-analysis, rate after first dose is from 1 study with 111 patients, rate after second dose is pooled across included studies of patients with CLL.
CLL = chronic lymphocytic leukemia; n = number of patients; NA = not available.